Wang Yun, Kringen Pedro, Kristensen Gunnar B, Holm Ruth, Baekelandt Mark M O, Olivier Magali, Skomedal Hanne, Hainaut Pierre, Tropé Claes G, Abeler Vera M, Nesland Jahn M, Børresen-Dale Anne-Lise, Helland Aslaug
Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo, Norway.
Hum Mutat. 2004 Jul;24(1):21-34. doi: 10.1002/humu.20055.
This study was conducted to evaluate the frequency and prognostic impact of TP53 alterations stratified for the TP53 codon 72 polymorphism (c.215G>C, p.Arg72Pro) in a cohort of 109 patients with advanced ovarian carcinomas. TP53 sequence variants were observed in 80 of the 109 (73.4%) tumors and were significantly associated with grade of differentiation (P=0.001). A tendency towards higher frequency of sequence variants in tumors with higher FIGO stages was seen (P=0.05). The type of TP53 sequence variant (transition A:T>G:C vs. G:C>A:T at CpG dinucleotides, and transversion G:C>T:A) had significant correlation with patients' age (P=0.04) with more A:T>G:C in patients over 60 years old. No significant associations were found between frequency of sequence variants and age at diagnosis, histological type, size of residual tumor after primary surgery, or long-term survival. Analyses of the codon 72 polymorphism in tumor DNA gave a higher frequency of homozygosity/hemizygosity than expected from the population frequency, particularly for the Pro allele. Tumors homozygous or hemizygous for the Pro allele had significantly higher frequency of TP53 sequence variants, particularly of the nonmissense type (P=0.002), and patients with these types of alterations had significantly shorter survival (P=0.04). TP53 protein accumulation, determined by immunohistochemistry (IHC), was found in 67.9% (74 out of 109) of the tumors, was significantly more common among serous than nonserous ovarian carcinomas (P=0.008), and had a significant effect on progression-free survival (P=0.03). p63 (TP73L; formerly TP63) and p73 (TP73) protein accumulation detected by IHC was seen in 67.9 and 0% of the tumors, respectively. A significantly higher frequency of p63-positive cases was seen among serous tumors (P=0.008) and tended to increase with increasing FIGO stages (P=0.05), but had no significant effect on survival. No association between p63 protein accumulation and TP53 protein accumulation was seen.
本研究旨在评估109例晚期卵巢癌患者队列中,根据TP53密码子72多态性(c.215G>C,p.Arg72Pro)分层的TP53改变的频率及其预后影响。109例肿瘤中有80例(73.4%)观察到TP53序列变异,且与分化程度显著相关(P=0.001)。FIGO分期较高的肿瘤中序列变异频率有升高趋势(P=0.05)。TP53序列变异类型(CpG二核苷酸处的转换A:T>G:C与G:C>A:T,以及颠换G:C>T:A)与患者年龄显著相关(P=0.04),60岁以上患者中A:T>G:C更多。序列变异频率与诊断时年龄、组织学类型、初次手术后残留肿瘤大小或长期生存之间未发现显著关联。对肿瘤DNA中密码子72多态性的分析显示,纯合子/半合子频率高于人群频率预期,尤其是Pro等位基因。Pro等位基因纯合或半合子的肿瘤中TP53序列变异频率显著更高,尤其是非错义类型(P=0.002),有这些类型改变的患者生存时间显著更短(P=0.04)。通过免疫组织化学(IHC)测定,67.9%(109例中的74例)肿瘤中发现TP53蛋白积累,在浆液性卵巢癌中比非浆液性卵巢癌更常见(P=0.008),且对无进展生存期有显著影响(P=0.03)。通过IHC检测到p63(TP73L;原TP63)和p73(TP73)蛋白积累分别见于67.9%和0%的肿瘤。浆液性肿瘤中p63阳性病例频率显著更高(P=0.008),且有随FIGO分期增加而升高的趋势(P=0.05),但对生存无显著影响。未发现p63蛋白积累与TP53蛋白积累之间存在关联。